Skip to main content

Table 1 Baseline characteristics

From: Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

 

Evolocumab

(n = 16)

Placebo

(n = 14)

P value

Age, years

58.6 (7.6)

61.4 (7.5)

0.317

Gender, n male (%)

7 (44)

7 (50)

0.732

BMI, kg/m2

25.5 (3.4)

26.6 (4.0)

0.493

Smoking, n active (%)

2 (13)

0 (0)

0.171

SBP, mmHg

137 (16)

139 (12)

0.574

DBP, mmHg

82 (8)

86 (8)

0.317

CVD, n (%)

3 (19)

1 (7)

0.351

Medication use, n (%)

 Statins

11 (69)

7 (50)

0.296

 Ezetimibe

3 (19)

4 (29)

0.526

 Total cholesterol, mmol/La

5.46 (0.92)

5.62 (0.76)

0.603

 LDL-cholesterol, mmol/La

3.36 (0.70)

3.68 (0.68)

0.197

 HDL-cholesterol, mmol/La

1.46 (0.43)

1.35 (0.37)

0.519

 Triglycerides, mmol/Lb

1.38 [1.19–1.54]

1.28 [0.91–1.63]

0.533

 ApoB, g/l

1.00 [0.93–1.15]

1.07 [0.92–1.17]

0.633

 Lipoprotein(a), nmol/Lc

254 [182–297]

154 [138–300]

0.430

 hs-CRP, g/l

0.75 [0.58–1.58]

1.05[0.53–1.92]

0.546

  1. Data are mean (SD), median [interquartile range], or n (%). ApoB, apolipoprotein B; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); SBP, systolic blood pressure
  2. aTo convert to mg/dL, multiply by 38.7, b To convert to mg/dL, multiply by 88.6, c To convert to mg/dL, divide by 2.5
  3. Wilcoxon rank-sum test was used to calculate P values for Age, BMI, SBP, DBP, Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides ApoB, Lipoprotein(a) and hs-CRP
  4. Chi square test was used to calculate P values for Gender, Smoking, Statins and Ezetimibe